Formycon AG has entered into a partnership with NTC s.r.l. for the exclusive commercialization of its Eylea® biosimilar FYB203 in Italy.
Information on the Target
Formycon AG is a leading independent developer of high-quality biosimilars focused on biopharmaceutical treatments, with an emphasis on ophthalmology and other critical disease areas. The company oversees the entire development process, from initial technical development through clinical trials to regulatory approval. Formycon’s latest biosimilar, FYB203 (aflibercept), has gained approval from the FDA, EMA, and MHRA, positioning itself as a strong competitor in the treatment of age-related eye diseases.
In an announcement dated November 24, 2025, Formycon revealed that NTC s.r.l. will serve as the exclusive commercialization partner for FYB203 in Italy. This partnership will enable Klinge Biopharma GmbH, the exclusive owner of global commercialization rights for FYB203, to leverage NTC's expertise and market presence in Italy.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Italy
The Italian pharmaceutical industry is recognized as one of the largest and most sophisticated markets in Europe, backed by a robust healthcare system and strong government support for research
Similar Deals
Antin Infrastructure Partners → Hippocrates
2021
Boston Scientific → Nalu Medical
2026
Barça Innovation Hub → Omniscope
2025
NTC s.r.l.
invested in
Formycon’s Eylea® biosimilar FYB203/Baiama®
in 2025
in a Strategic Partnership deal